Lexicon to Present Analyses of INPEFA (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

INPEFA recently approved by FDA for treatment of heart failure

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023, in Amsterdam, The Netherlands and online.

On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

• heart failure or
  
• type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
  

Details of the two presentations are as follows:

• Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF – an oral presentation, Saturday, August 26, 4:00 – 4:10 p.m. CET, RAI Amsterdam Convention Center, Science Box 2 and online, presented by Bertram Pitt, M.D., FACC, professor of medicine emeritus at the University of Michigan, School of Medicine, Ann Arbor, MI
  
• Temporal shift in heart failure diagnoses among hospitalized patients within a large US integrated health system – a moderated ePoster presentation, Saturday, August 26, 2:45 – 2:50 p.m. CET, RAI Amsterdam Convention Center, Station 3 and online, presented by Marc Bonaca, M.D., M.P.H., University of Colorado Anschutz Medical Campus, Aurora, CO
  

About INPEFA (sotagliflozin)

Discovered using Lexicon’s unique approach to gene science, INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose reabsorption by the kidney and SGLT1 is responsible for glucose absorption in the gastrointestinal tract. INPEFA has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.